Bayer Aktiengesellschaft Bayer Aktiengesellschaft

Bayer Aktiengesellschaft

BAYN

주식 순위 #489
Bayer Aktiengesellschaft operates as a life science company in Europe, the... Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment offers nonprescription over-the-counter medicines for self-medication and self-care; nutritional supplements; allergy, cough, and cold; dermatology; pain and cardiovascular risk prevention; and digestive health products. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solutions, and pest and weed management products, as well as customer services for agriculture. It also engages in the breeding, propagation, and production/processing of seeds, including seed dressing. The company distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.
주가
$50.31
마지막 동기화: 2026-10-21
시가총액
$49.43B
변동 (1일)
-2.45%
변동 (1년)
57.43%
국가
DE
거래 Bayer Aktiengesellschaft (BAYN)

카테고리

Healthcare
Bayer Aktiengesellschaft (BAYN)의 수익
2026 기준 수익 TTM: 0
Bayer Aktiengesellschaft의 최신 재무 보고서에 따르면 회사의 현재 수익은 0입니다. 2026년에 회사는 0의 수익을 올렸으며 이는 2026년의 수익 0과 동일입니다. 이 페이지에 표시된 수익은 이자 및 세금 공제 전 수익으로, 즉 EBIT입니다.
Bayer Aktiengesellschaft의 수익 기록 (2026 ~ 2026)
연말 수익
연도 수익 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 수익
회사 수익 수익 차이 국가
$33.60B -
US
$17.74B -
US
$8.70B -
US
$5.95B -
US
$21.39B -
CH